Roche Pharmaceutical Development and Sales Overview

Herceptin Global sales CHFbn CER growth -18% Regional sales CER growth US -28% 5.4 Europe -13% 4.5 Japan -28% 3.6 2.7 1.8 0.9 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 International -15% YTD Sep 2022 sales of CHF 1,672m • • US: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo EU: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Cannibalization from Phesgo • Japan: Decline due to biosimilars International: Decline due to biosimilars; Cannibalization from Phesgo CER-Constant Exchange Rates Roche 156

View entire presentation